Short Interest in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Rises By 15.5%

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 18,910,000 shares, a growth of 15.5% from the November 15th total of 16,370,000 shares. Based on an average daily volume of 2,410,000 shares, the days-to-cover ratio is currently 7.8 days.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares of the company's stock, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.20% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NTLA. Blue Trust Inc. raised its position in shares of Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company's stock valued at $33,000 after buying an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock worth $39,000 after buying an additional 1,550 shares during the last quarter. Eastern Bank acquired a new position in shares of Intellia Therapeutics during the third quarter worth $41,000. Values First Advisors Inc. bought a new position in shares of Intellia Therapeutics in the 3rd quarter valued at $54,000. Finally, First Horizon Advisors Inc. boosted its holdings in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock valued at $58,000 after acquiring an additional 472 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NTLA. Chardan Capital lifted their price objective on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a "buy" rating in a report on Monday, November 18th. StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a research report on Friday, November 8th. Oppenheimer decreased their price objective on Intellia Therapeutics from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Monday, November 11th. Citigroup lowered their target price on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Finally, Robert W. Baird reduced their price target on Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $54.94.

Intellia Therapeutics Price Performance

NTLA traded down $0.66 during trading on Friday, hitting $12.90. The stock had a trading volume of 3,187,759 shares, compared to its average volume of 1,760,464. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -2.37 and a beta of 1.76. The company has a 50 day moving average price of $16.13 and a 200-day moving average price of $20.60. Intellia Therapeutics has a one year low of $12.47 and a one year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same period in the previous year, the firm posted ($1.38) EPS. The company's revenue was down 24.1% compared to the same quarter last year. As a group, sell-side analysts predict that Intellia Therapeutics will post -5.12 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.